CAJ | 학술논문

目的探讨甲状腺乳头状癌组织中触珠蛋白(Hp)的表达及意义.方法采用反转录-聚合酶链反应(RT-PCR)、Western blot技术检测甲状腺乳头状癌组织、结节性甲状腺肿及正常甲状腺组织中Hp mRNA和蛋白的表达.结果甲状腺乳头状癌组织中Hp mRNA的相对表达量(0.913 ±0.102)明显高于结节性甲状腺肿(0.357±0.009)和正常甲状腺组织(0.296 ±0.008).Hp蛋白在甲状腺乳头状癌组织中的相对表达量为0.892 ±0.122,显著高于结节性甲状腺肿(0.211 ±0.051)和正常甲状腺组织(0.197±0.046,P＜0.05),而后两者之间差异无统计学意义(P＞0.05).随着TNM分期的增加,Hp mRNA和蛋白表达水平有升高的趋势,但各分期间的表达差异无统计学意义(P＞0.05).结论 Hp在甲状腺乳头状癌的发生发展中发挥重要作用.
목적 탐토갑상선유두상암조직중촉주단백(Hp)적표체급의의.방법 채용반전록-취합매련반응(RT-PCR)、Western blot기술검측갑상선유두상암조직、결절성갑상선종급정상갑상선조직중Hp mRNA화단백적표체.결과 갑상선유두상암조직중Hp mRNA적상대표체량(0.913 ±0.102)명현고우결절성갑상선종(0.357±0.009)화정상갑상선조직(0.296 ±0.008).Hp단백재갑상선유두상암조직중적상대표체량위0.892 ±0.122,현저고우결절성갑상선종(0.211 ±0.051)화정상갑상선조직(0.197±0.046,P＜0.05),이후량자지간차이무통계학의의(P＞0.05).수착TNM분기적증가,Hp mRNA화단백표체수평유승고적추세,단각분기간적표체차이무통계학의의(P＞0.05).결론 Hp재갑상선유두상암적발생발전중발휘중요작용.
Objective To explore the expression and significance of haptoglobin (Hp) in papillary thyroid carcinoma.Methods Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blotting were applied to detect the expression of Hp in 112 cases of papillary thyroid carcinoma,67 cases of benign thyroid node and 50 cases of normal thyroid tissues.Results The relative expression value of Hp mRNA was (0.913 ±0.102) in papillary thyroid carcinoma tissues,which were over-expressed comparing with benign thyroid node (0.357 ± 0.009) and normal thyroid tissue (0.296 ± 0.008) groups (P ＜ 0.05).The relative expression value of Hp protein was (0.892 ± 0.122) in papillary thyroid carcinoma tissues,which were up-regulated comparing with benign thyroid node (0.211 ±0.051) and normal thyroid tissue (0.197 ± 0.046) groups (P ＜ 0.05).However,there was no statistical significance between benign thyroid node and normal thyroid tissues (P ＞ 0.05).In addition,although the level of Hp mRNA increased with the higher clinical stages,there were no statistical significance (P ＞ 0.05).Condusion Our results suggested that Hp might play a key role in papillary thyroid carcinoma occurrence.Moreover,findings in the present study also provided evidence for the diagnostic and therapeutic strategies in the treatment of papillary thyroid carcinoma.